Effect of Number of Previous Antiseizure Medications on Efficacy and Tolerability of Adjunctive Brivaracetam for Uncontrolled Focal Seizures: Post Hoc Analysis

[1] Lynch BA(2004)The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc Natl Acad Sci USA 101 9861-9866

[2] Lambeng N(2011)Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties Eur J Pharmacol 664 36-44

[3] Nocka K(2016)Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment Epilepsia 57 538-548

[4] Gillard M(2015)Brivaracetam augments short-term depression and slows vesicle recycling Epilepsia 56 1899-1909

[5] Fuks B(2017)Brivaracetam does not modulate ionotropic channels activated by glutamate, gamma-aminobutyric acid, and glycine in hippocampal neurons Epilepsia 58 e157-e161

[6] Leclercq K(2014)Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial Epilepsia 55 57-66

[7] Matagne A(2010)Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial Neurology 75 519-525

[8] Klitgaard H(2015)A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures Epilepsia 56 1890-1898

[9] Matagne A(2014)Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial Epilepsia 55 47-56

[10] Nicolas JM(2013)Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial Epilepsia 54 89-97

[1] Lynch BA(2004)The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc Natl Acad Sci USA 101 9861-9866

[2] Lambeng N(2011)Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties Eur J Pharmacol 664 36-44

[3] Nocka K(2016)Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment Epilepsia 57 538-548

[4] Gillard M(2015)Brivaracetam augments short-term depression and slows vesicle recycling Epilepsia 56 1899-1909

[5] Fuks B(2017)Brivaracetam does not modulate ionotropic channels activated by glutamate, gamma-aminobutyric acid, and glycine in hippocampal neurons Epilepsia 58 e157-e161

[6] Leclercq K(2014)Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial Epilepsia 55 57-66

[7] Matagne A(2010)Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial Neurology 75 519-525

[8] Klitgaard H(2015)A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures Epilepsia 56 1890-1898

[9] Matagne A(2014)Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial Epilepsia 55 47-56

[10] Nicolas JM(2013)Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial Epilepsia 54 89-97